Akari Therapeutics Plc Funding: $6.25M Raised (Form D)

Keep reading

More on the people and the money behind Akari Therapeutics Plc, from the filings we hold.

More raises like this

Other Health Care raises by companies based in Florida, filed in October 2025, largest first.

CURADEL SURGICAL INNOVATIONS, INC. $14.5M, Oct 2025
Fountains of Hope, LLC $1M, Oct 2025

What do you want to do with Akari Therapeutics Plc?

Who the filing names, and in what role

Abizer Gaslightwala is listed as Executive Officer and Director of Akari Therapeutics Plc on its Form D filed October 24, 2025, described there as “President and Chief Executive Officer”.

Kameel Farag is listed as Executive Officer of Akari Therapeutics Plc on its Form D filed October 24, 2025, described there as “Interim Chief Financial Officer”.

Rob Bazemore is listed as Director of Akari Therapeutics Plc on its Form D filed October 24, 2025.

Hoyoung Huh is listed as Director of Akari Therapeutics Plc on its Form D filed October 24, 2025.

Jim Neal is listed as Director of Akari Therapeutics Plc on its Form D filed October 24, 2025.

Ray Prudo is listed as Director of Akari Therapeutics Plc on its Form D filed October 24, 2025.

Samir Patel is listed as Director of Akari Therapeutics Plc on its Form D filed October 24, 2025.

Sandip Patel is listed as Director of Akari Therapeutics Plc on its Form D filed October 24, 2025.

The filing gives Akari Therapeutics Plc's address as 401 East Jackson Street, Suite 3300, Tampa, FL 33602.

What the filing says

Offered: $6,250,000. Sold: $6,250,000. Left to sell: nothing, all of it is sold. (filing)
Investors: 4 had already invested. (filing)
Date of first sale: October 16, 2025. (filing)
Types of securities: Options, warrants or other rights to acquire another security; Securities to be acquired on exercise of an option, warrant or other right; Other: American Depositary Shares (ADSs), each representing 2,000 Ordinary Shares. (filing)
Item 16: the filing reports that none of the proceeds goes to executive officers, directors or promoters. It adds: “The Company intends to use the net proceeds for working capital, general corporate purposes, and continued research and development.” (filing)
On the amounts offered and sold: the filing adds “Reflects proceeds from the exercise of 6,250,000 warrants (comprising 3,125,000 Series E and 3,125,000 Series F warrants, each with an ex. price of $0.98/ADS, and 125,000 placement agent warrants with an ex. price of $1.00/ADS).” (filing)
On sales commissions and finders' fees: the filing adds “Ladenburg Thalmann is also entitled to a mgmt. fee equal to 0.5% of the gross proceeds, reimbursement of up to $75,000, and 125,000 warrants to purchase ADSs exercisable at $1.00 per share for five years.” (filing)

This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.

Order the Full Report on Akari Therapeutics Plc See pricing

Is Akari Therapeutics Plc a real, registered company?

Akari Therapeutics Plc is a registered filer with the SEC (CIK 1541157) and has filed since 2023-10-19. 4 filings are on record, the latest on 2026-06-03.

A filing shows the company exists and what it reports about itself. It is not an audit or a rating.

Who runs Akari Therapeutics Plc?

Akari Therapeutics Plc's Form D of 2025-10-24 names Abizer Gaslightwala, Kameel Farag, Rob Bazemore and 5 more as its officers, directors or promoters.

How much has Akari Therapeutics Plc raised?

Its new offerings report $12.05M sold across 4 offerings, as its own filings state.

Filing history · 4 filings on this registrant

Each marker is one filing. The larger marker is the filing this page is about.

Other Health Care · by week

Trailing twelve months. 871 filings in Other Health Care, totalled by week.

Company officers on record

Abizer Gaslightwala

President and Chief Executive Officer

On the filing as: Executive Officer, Director.

TAMPA, FLORIDA

Abizer Gaslightwala is named as President and Chief Executive Officer on the Form D that Akari Therapeutics Plc filed with the SEC on 24 October 2025, one of 8 people that filing names.

Kameel Farag

Interim Chief Financial Officer

On the filing as: Executive Officer.

TAMPA, FLORIDA

Kameel Farag is named as Interim Chief Financial Officer on the Form D that Akari Therapeutics Plc filed with the SEC on 24 October 2025, one of 8 people that filing names.

Rob Bazemore

Director

TAMPA, FLORIDA

Rob Bazemore is named as Director on the Form D that Akari Therapeutics Plc filed with the SEC on 24 October 2025, one of 8 people that filing names.

Hoyoung Huh

Director

TAMPA, FLORIDA

Hoyoung Huh is named as Director on the Form D that Akari Therapeutics Plc filed with the SEC on 24 October 2025, one of 8 people that filing names.

Jim Neal

Director

TAMPA, FLORIDA

Jim Neal is named as Director on the Form D that Akari Therapeutics Plc filed with the SEC on 24 October 2025, one of 8 people that filing names.

Ray Prudo

Director

TAMPA, FLORIDA

Ray Prudo is named as Director on the Form D that Akari Therapeutics Plc filed with the SEC on 24 October 2025, one of 8 people that filing names.

Samir Patel

Director

TAMPA, FLORIDA

Samir Patel is named as Director on the Form D that Akari Therapeutics Plc filed with the SEC on 24 October 2025, one of 8 people that filing names.

Sandip Patel

Director

TAMPA, FLORIDA

Sandip Patel is named as Director on the Form D that Akari Therapeutics Plc filed with the SEC on 24 October 2025, one of 8 people that filing names.

8 people named on the filing — 2 holding an executive role and 6 as directors only.

Named as of the 2025-10-24 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.

Want the whole picture on Akari Therapeutics Plc?

What the filing shows about Akari Therapeutics Plc

4 investors had already put money in when it filed.
The filing names 8 people as officers, directors or promoters.

Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.

Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)

A Full Report on Akari Therapeutics Plc: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Akari Therapeutics Plc covers

The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
1 cited source found

Plus the sections for what you are deciding, which you pick after ordering.

See a sample report

First screen of a real sample Full Report on EchoStar: the verdict, 17 sections, 63 cited sources, built 2026-10-21

A real finished report, first screen. Opens in a new tab.

The full profile

Checking your access…

Is this you?

If you're behind Akari Therapeutics Plc: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.

Sourced from the filing index on sec.gov.

Cite this page

Permanent URL: https://mentionfox.com/funding/akari-therapeutics-plc-form-d-25000001

Last updated 2026-10-30

Akari Therapeutics Plc raised $6.25M — SEC Form D filing, October 2025. MentionFox, 2026-10-30. https://mentionfox.com/funding/akari-therapeutics-plc-form-d-25000001

Akari Therapeutics Plc — $6.25M Form D filing, October 2025

Key facts